Written Question·Department of Health and Social Care·UIN 96433

Glioblastoma: Immunotherapy

Tabled: 2 December 2025
Answered: 8 December 2025

Question

Jack Rankin

ConservativeWindsor

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of DCVax-L following its trial at King’s College Hospital.

Answer

Dr Zubir Ahmed
The Department has made no assessment of the potential merits of DCVax-L following its trial at King’s College Hospital.Northwest Biotherapeutics has submitted a Marketing Authorisation Application to the Medicines and Healthcare products Regulatory Agenc...

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 96433) →